SNDX logo

SNDX
Syndax Pharmaceuticals Inc

3,789
Mkt Cap
$1.69B
Volume
517,353.00
52W High
$25.59
52W Low
$8.58
PE Ratio
-5.80
SNDX Fundamentals
Price
$20.22
Prev Close
$19.11
Open
$19.28
50D MA
$22.91
Beta
1.14
Avg. Volume
1.49M
EPS (Annual)
-$3.29
P/B
25.84
Rev/Employee
$578,362.42
$1,771.37
Loading...
Loading...
News
all
press releases
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% on Analyst Upgrade...
MarketBeat·46m ago
News Placeholder
More News
News Placeholder
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at HC Wainwright increased their FY2030 EPS estimates for Syndax Pharmaceuticals in a note issued to investors on Friday, May 1st. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of $3...
MarketBeat·9h ago
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1% - Time to Sell?
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.1% - Should You Sell...
MarketBeat·3d ago
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00
Barclays raised their price target on Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a research note on Friday...
MarketBeat·3d ago
News Placeholder
Syndax Pharmaceuticals Q1 Earnings Call Highlights
Syndax Pharmaceuticals (NASDAQ:SNDX) reported first-quarter 2026 results highlighting more than $100 million in combined net sales for its two commercial products, Revuforj and Niktimvo, as the...
MarketBeat·4d ago
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.59) by...
MarketBeat·4d ago
News Placeholder
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Nuvation Bio (NUVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
Syndax Pharmaceuticals (SNDX) Expected to Announce Earnings on Thursday
Syndax Pharmaceuticals (NASDAQ:SNDX) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-syndax-pharmaceuticals-inc-stock...
MarketBeat·7d ago
News Placeholder
Torray Investment Partners LLC Invests $2.06 Million in Syndax Pharmaceuticals, Inc. $SNDX
Torray Investment Partners LLC purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the 4th quarter, according to the company in its most recent...
MarketBeat·11d ago
<
1
2
...
>

Latest SNDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.